September 4, 2024 07:36 AM EDTUpdated September 6, 11:35 PM

Roche unveils more mid-stage data for BTK inhibitor in relapsing multiple sclerosis

Katherine Lewin

News Reporter

Roche touted new Phase 2 data for its BTK inhibitor fenebrutinib in relapsing multiple sclerosis, noting that patients on the drug maintained low levels of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche unveils more mid-stage data for BTK inhibitor in relapsing multiple sclerosis

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Roche un­veils more mid-stage da­ta for BTK in­hibitor in re­laps­ing mul­ti­ple scle­ro­sis

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roche unveils more mid-stage data for BTK inhibitor in relapsing multiple sclerosis